DL FOI 24.25 0120 Deep Vein Thrombosis Pulmonary Embolism.pdf

DOCUMENT 10
FOI-24/25-0120
Research – Venous Thromboembolism (Deep Vein Thrombosis and
Pulmonary Embolism): Evidence Based Treatment
Evidence Based Treatments for Venous Thromboembolism (Deep Vein
Brief
Thrombosis and Pulmonary Embolism)
Date
20 January 2021
Requester(s)
Alicia s47F - personal privacy (Senior Technical Advisor (TAB/AAT)
Researcher
Craig

s47F - persona ( Tactical Research Advisor – TAB/AAT)
Cleared
Jane s47F - personal priva(Research Team Leader - TAB)
Please note:
The research and literature reviews collated by our TAB Research Team are not to be shared external to the Branch. These
are for internal TAB use only and are intended to assist our advisors with their reasonable and necessary decision-making.
Delegates have access to a wide variety of comprehensive guidance material. If Delegates require further information on
access or planning matters they are to call the TAPS line for advice.
The Research Team are unable to ensure that the information listed below provides an accurate & up-to-date snapshot of
these matters.
1  Contents
2
Summary ......................................................................................................................................... 2
3
Introduction .................................................................................................................................... 2
4
What is Venous Thromboembolism (VTE)? .................................................................................... 2
5
Treatment of Venous Thromboembolism ...................................................................................... 3
5.1
Overview ................................................................................................................................. 3
5.2
Anticoagulant therapy for deep vein thrombosis and pulmonary embolism ........................ 3
5.2.1
Duration of anticoagulation ............................................................................................ 4
6
Invasive strategies for VTE management........................................................................................ 5
7
References ...................................................................................................................................... 6
Research – Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism): Evidence Based Treatment |     Page | 1
Page 1 of 7

FOI-24/25-0120

2  Summary

•  Venous Thromboembolism (VTE) is a disease which includes Deep Vein Thrombosis (DVT)
and Pulmonary Embolism (PE). DVT and PE are both forms of VTE, but they’re not the same
condition

•  The treatment for DVT depends on its anatomical extent (proximal or distal)

•  Initial treatment for DVT are anticoagulation medications used to prevent blood clots

•  Severe VTE requires additional invasive/surgical measures

3  Introduction

This document summarizes the evidence based research detailed in the 2019 guidelines produced by
the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) which aims to
promote evidence based optimal management of VTE [1, 2].
In the development of the guidelines, a Venous Thromboembolism (VTE) writing group was
established within THANZ and comprised of experts in the field of thromboembolic disorders in
Australian and New Zealand. All members undertook a detailed literature review and critically
appraised existing evidence on the diagnosis and treatment of VTE. Drafts of evidence‐based
recommendations, practice points and a background manuscript were developed. The
recommendations follow the National Health and Medical Research Council levels of evidence and
the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to
determine the strength of the recommendations [1].
4  What is Venous Thromboembolism (VTE)?

VTE is a chronic and frequently recurrent disease that includes deep vein thrombosis (DVT) and
pulmonary embolism (PE). DVT and PE are both forms of VTE, but are not the same thing [3]. It is a
potentially preventable disease, however, can result in complications such as post-thrombotic
syndrome, pulmonary hypertension, recurrent thrombosis, or death.
In DVT a blood clot usually forms in the deep veins of the calf, thigh, or pelvis which may or may not
cause symptoms such as swelling, redness or pain. In some people, clots resolve spontaneously,
however there is a risk that some or all of the clot may break away and travel to the lungs, resulting
in PE. This can cause respiratory symptoms, heart failure or death [4].
VTE can be fatal if untreated; long term morbidity includes post-thrombotic syndrome (PTS) and
pulmonary hypertension. Symptoms of VTE are non-specific, and the diagnosis should actively be
sought once considered. A diagnosis of VTE has an impact on subsequent pregnancies, oestrogen
use, surgery, life insurance and, occasionally, long-haul travel [5].
Research – Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism): Evidence Based Treatment |     Page | 2
Page 2 of 7

FOI-24/25-0120

VTE is the third most common cardiovascular disease, with an annual incidence of more than 10
million people globally [6]. In Australia, at least 17,000 people develop VTE each year (annual
incidence, 0.83 per 1,000 population) [7]. The lifetime risk of VTE is 8%, with 1% of people aged over
80 years experiencing their first VTE. This disease is a major cause of health-related economic loss
for patient’s and the community (estimated to be $1.7 billion for Australia in 2008) [8].

5  Treatment of Venous Thromboembolism

5.1  Overview

•  The spectrum of VTE ranges from distal DVT, which may not require anticoagulation
(medications that help prevent blood clots), through to proximal DVT to potentially life-
threatening PE requiring additional invasive strategies. The treatment for DVT depends on
its anatomical extent: in proximal DVT, thrombus is present in the popliteal (and its
trifurcation) or a more proximal vein; in distal DVT, thrombus only occurs in the tibial,
peroneal, gastrocnemius and soleal veins [9].

•  Anticoagulation is indicated in most cases of VTE because it is highly effective in preventing
thrombus extension or recurrence by at least 80% [10].

5.2  Anticoagulant therapy for deep vein thrombosis and pulmonary embolism

•  Direct oral anticoagulants (DOACs) and warfarin are equally effective and can be prescribed
to most patients. GRADE: Strong; Evidence: High [10, 11].

•  DOACs do not require routine monitoring, have no known food interactions and few drug
interactions, and are favoured in most instances. However, DOACs should not be used
during pregnancy or breastfeeding, in which case low molecular weight heparin is indicated
[10].

•  Edoxaban and rivaroxaban have been shown to be as efficacious as dalteparin in cancer-
related thrombosis, but are associated with an increased risk for major bleeding or clinically
relevant non-major bleeding (CRNMB) and, therefore, can be considered when appropriate
[12, 13].

•  Oral factor Xa inhibitors (eg, apixaban, rivaroxaban) are preferred to dabigatran or warfarin
to treat proximal DVT and PE because they do not require parenteral anticoagulation for
initiation. GRADE: Strong; Evidence: High [10].

Research – Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism): Evidence Based Treatment |     Page | 3
Page 3 of 7

FOI-24/25-0120

5.2.1  Duration of anticoagulation

5.2.1.1  Proximal deep vein thrombosis and pulmonary embolism

•  All patients with proximal DVT and PE should receive anticoagulant therapy for at least 3
months. GRADE: Strong; Evidence: Strong [10].

•  Patients whose proximal DVT or PE were provoked by major surgery or major trauma can
cease anticoagulation at this time [10].

5.2.1.2  Distal deep vein thrombosis

•  Uncertainty exists about the value of anticoagulation for distal DVT. In general,
anticoagulation is used for proximal DVT and PE, but serial duplex ultrasound (two duplex
ultrasound scans over 2 weeks) is reasonable (GRADE: Strong; Evidence: Moderate),
especially if the risk of bleeding is increased. Most distal DVT can be treated for 6 – 12
weeks. GRADE: Strong; Evidence: Moderate [14].

5.2.1.3  Extended anticoagulation for deep vein thrombosis and pulmonary embolism
(beyond 3–6 months)

•  For patients whose events were unprovoked or associated with transient risk factors (non-
surgical), decide whether to stop or to continue with extended anticoagulant therapy after 3
months of anticoagulation. Continuing therapy for longer than 3 months reduces the risk of
VTE recurrence during therapy by at least 80% but is associated with a major bleeding risk of
< 1% per year. Once anticoagulant therapy is stopped, the risk of recurrence is the same as
for patients who cease treatment after 3 – 6months when followed up over time [13].

•  Aspirin (100 mg daily) reduces the rate of VTE recurrence to a much lesser extent than oral
anticoagulants but is associated with similar rates of bleeding to rivaroxaban 10 mg daily
[15, 16]. Therefore, aspirin should be avoided, unless anticoagulation cannot be used.
GRADE: Strong; Evidence: High

Research – Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism): Evidence Based Treatment |     Page | 4
Page 4 of 7

FOI-24/25-0120

6  Invasive strategies for VTE management

•  Invasive treatment modalities for acute removal of thrombosis have been investigated, with
the goals of rapidly relieving acute right ventricular pressure overload in PE and thereby
improving survival or rapidly relieving venous obstruction to prevent vein dysfunction and
PTS and reduce VTE recurrence [5].

•  The following strategies have been investigated with variable results [17-20]:
o  Systemic administration of thrombolytic agents
o  Catheter-directed thrombolysis, which uses lower thrombolytic doses with or
without the addition of mechanical clot disruption
o  Acute surgical thrombectomy
Research – Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism): Evidence Based Treatment |     Page | 5
Page 5 of 7

FOI-24/25-0120

7. References

1.
Tran HA, Gibbs H, Merriman E, Curnow JL, Young L, Bennett A, et al. The Diagnosis and
Management of Venous thromboembolism – Guidelines of the Thrombosis and Haemostasis Society
of Australia and New Zealand2019. Available from: https://www.thanz.org.au/documents/item/411.
2.
Thrombosis and Haemostasis Society of Australia and New Zealand. About Us 2021
[Available from: https://www.thanz.org.au/about-us/about-us.
3.
Healthline. What’s the Difference Between Deep Vein Thrombosis (DVT) and Pulmonary
Embolism (PE)? 2021 [Available from: https://www.healthline.com/health/dvt-vs-pulmonary-
embolism.
4.
Australian Commission on Safety and Quality in Health Care. Venous Thromboembolism
Prevention Clinical Care Standard (January 2020)2020. Available from:
https://www.safetyandquality.gov.au/sites/default/files/2020-
01/venous thromboembolism prevention clinical care standard - jan 2020 2.pdf.
5.
Tran HA, Gibbs H, Merriman E, Curnow JL, Young L, Bennett A, et al. New guidelines from the
Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and
management of venous thromboembolism. Medical Journal of Australia [Internet]. 2019;
210(5):[227-35 pp.]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.5694/mja2.50004.
6.
Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, et al. Thrombosis.
Arteriosclerosis, Thrombosis, and Vascular Biology [Internet]. 2014; 34(11):[2363-71 pp.]. Available
from: https://www.ahajournals.org/doi/abs/10.1161/ATVBAHA.114.304488.
7.
Ho WK, Hankey GJ, Eikelboom JW. The incidence of venous thromboembolism: a
prospective, community-based study in Perth, Western Australia. Medical Journal of Australia
[Internet]. 2008; 189(3):[144-7 pp.]. Available from:
https://onlinelibrary.wiley.com/doi/abs/10.5694/j.1326-5377.2008.tb01947.x.
8.
Fletcher J, Baker R, C CF, et al. The burden of venous thromboembolism in Australia. Access
Economics [Internet]. 2008. Available from: https://www.safetyandquality.gov.au/wp-
content/uploads/2018/10/Access-Economics The-burden-of-VTE-inAustralia 2008.pdf.
9.
PALARETI G, SCHELLONG S. Isolated distal deep vein thrombosis: what we know and what
we are doing. Journal of Thrombosis and Haemostasis [Internet]. 2012; 10(1):[11-9 pp.]. Available
from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1538-7836.2011.04564.x.
10.
Kearon C, Akl E, Ornelas J, et a. Antithrombotic Therapy for VTE Disease: CHEST Guideline.
Chest [Internet]. 2016; 149:[315–52 pp.]. Available from: https://journal.chestnet.org/article/S0012-
3692(15)00335-9/fulltext.
11.
Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin
in high-risk patients with antiphospholipid syndrome. Blood [Internet]. 2018; 132(13):[1365-71 pp.].
Available from: https://doi.org/10.1182/blood-2018-04-848333.
12.
Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the
Treatment of Cancer-Associated Venous Thromboembolism. New England Journal of Medicine
[Internet]. 2017; 378(7):[615-24 pp.]. Available from:
https://www.nejm.org/doi/full/10.1056/NEJMoa1711948.
13.
Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral
Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous
Thromboembolism: Results of a Randomized Trial (SELECT-D). Journal of Clinical Oncology [Internet].
2018; 36(20):[2017-23 pp.]. Available from:
https://ascopubs.org/doi/abs/10.1200/JCO.2018.78.8034.
14.
Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, et al. Influence of preceding
length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of
Research – Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism): Evidence Based Treatment | Page | 6
Page 6 of 7

FOI-24/25-0120

recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ
[Internet]. 2011; 24(342). Available from: https://www.bmj.com/content/342/bmj.d3036.
15.
Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, et al. Low-Dose Aspirin
for Preventing Recurrent Venous Thromboembolism. New England Journal of Medicine [Internet].
2012; 367(21):[1979-87 pp.]. Available from:
https://www.nejm.org/doi/full/10.1056/NEJMoa1210384.
16.
Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al.
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. New England Journal
of Medicine [Internet]. 2017; 376(13):[1211-22 pp.]. Available from:
https://www.nejm.org/doi/full/10.1056/NEJMoa1700518.
17.
Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for
Patients with Intermediate-Risk Pulmonary Embolism. New England Journal of Medicine [Internet].
2014; 370(15):[1402-11 pp.]. Available from:
https://www.nejm.org/doi/full/10.1056/NEJMoa1302097.
18.
Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, et al.
Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. New England
Journal of Medicine [Internet]. 2017; 377(23):[2240-52 pp.]. Available from:
https://www.nejm.org/doi/full/10.1056/NEJMoa1615066.
19.
Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis Compared With Heparin for the
Initial Treatment of Pulmonary Embolism. Circulation [Internet]. 2004; 110(6):[744-9 pp.]. Available
from: https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000137826.09715.9C.
20.
Sharifi M, Bay C, Skrocki L, et al. “MOPETT” Investigators. Moderate pulmonary embolism
treated with thrombolysis (from the “MOPETT” trial). Am J Cardiol [Internet]. 2003; 111:[273–7 pp.].
Available from: https://www.ajconline.org/article/S0002-9149(12)02205-9/fulltext.

Research – Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism): Evidence Based Treatment | Page | 7
Page 7 of 7